This web site is part of the Business Intelligence Division of Informa PLC
Malaria Vaccine (CRXL)
Johnson & Johnson
Drug Names(s): Malaria Vaccine (Crucell), AdVac.CS vaccine, Ad35.CS, Ad35-CS
Description: Crucell's malaria vaccine is based on its AdVac technology, in which genetic material from the disease-causing virus or parasite is inserted into a vector, which then delivers the immunogenic material directly to the immune system. AdVac technology is specifically designed to manage the problem of pre-existing immunity in humans against the most commonly used recombinant vaccine vector, adenovirus serotype 5 (Ad5), without compromising large-scale production capabilities or the immunogenic properties of Ad5. AdVac technology is based on adenovirus vectors that do not regularly occur in the human population, such as Ad11 and Ad35.
Deal Structure: In March 2004, it was announced that the Institute of Allergy and Infectious Diseases (NIAID) would support the development of an AdVac-based candidate malaria vaccine with Crucell. The agreement had an estimated value of up to US$3.5 million, covering process development of the candidate malaria vaccine including the production of clinical trial material and the Investigational New Drug (IND) filing. In September 2006, Crucell and the NIAID extended the collaboration with the signing of a clinical trial agreement.
In August 2010 Crucell entered into a collaboration with GSK to develop its second generation malaria vaccine.
In October 2010, Johnson & Johnson and Crucell announced an agreement whereby Johnson & Johnson, through an affiliate, would acquire all outstanding equity of Crucell that it does not already own for approximately Euro 1.75 billion in a recommended cash tender offer. The acquisition was declared unconditional and completed in February 2011.
Partners: GlaxoSmithKline plc
Malaria Vaccine (CRXL) News
Additional information available to subscribers only: